Document Detail


Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells.
MedLine Citation:
PMID:  12562860     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study determined the effects of apoA-I, HDL3, or hydroxy-beta-cyclodextrin on apoB-100 secretion and bile acid synthesis by HepG2 cells. The principal observations were that: 1) ApoB-100 secretion into the medium was significantly less after the addition of any of the three agents. 2) Triglyceride mass was not significantly changed from control in the medium but was significantly, although modestly, reduced in the cells. 3) Neither free cholesterol (FC) nor cholesteryl ester (CE) mass in the medium was changed; by contrast, CE mass was reduced within the cells although FC was not. 4) Although the total mass of cholesterol in the medium was unaffected, the proportion associated with apoB-100 was reduced, whereas the proportion associated with the non-apoB-100 fraction was increased. 5) There was also an unanticipated, but substantial, increase in bile acid synthesis induced by apoA-I, HDL3, or hydroxy-beta-cyclodextrin, which was time and concentration dependent, and which was associated with marked increases in cholesterol 7 alpha-hydroxylase activity. There were no significant changes in ACAT activity and only modest increases in HMG-CoA reductase activity. These findings support previous clinical observations that an elevated apoB-100 can accompany a low HDL cholesterol in normotriglyceridemic subjects. They also point to physiologically important, although still only partially understood, metabolic relationships amongst hepatic apoB-100 secretion, cholesterol efflux, and bile acid synthesis.
Authors:
Allan D Sniderman; ZuJun Zhang; Jacques Genest; Katherine Cianflone
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2002-12-16
Journal Detail:
Title:  Journal of lipid research     Volume:  44     ISSN:  0022-2275     ISO Abbreviation:  J. Lipid Res.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-04     Completed Date:  2003-06-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376606     Medline TA:  J Lipid Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  527-32     Citation Subset:  IM    
Affiliation:
Mike Rosenbloom Laboratories for Cardiovascular Research, Cardiovascular Genetics Laboratory, McGill University, Montreal, Canada. allan.sniderman@muhc.mcgill.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apolipoprotein A-I / pharmacology
Apolipoprotein B-100
Apolipoproteins B / secretion*
Bile Acids and Salts / biosynthesis*
Biological Transport / drug effects
Cholesterol / metabolism*
Cholesterol Esters / metabolism
Cyclodextrins / pharmacology
Dose-Response Relationship, Drug
Humans
Lipoproteins, HDL / pharmacology
Lipoproteins, HDL3
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Apolipoprotein B-100; 0/Apolipoproteins B; 0/Bile Acids and Salts; 0/Cholesterol Esters; 0/Cyclodextrins; 0/Lipoproteins, HDL; 0/Lipoproteins, HDL3; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different effects of n-6 and n-3 polyunsaturated fatty acids on the activation of rat smooth muscle ...
Next Document:  Regulation of human delta-6 desaturase gene transcription: identification of a functional direct rep...